Insights on Clinical Trials

1. What Can The Tech Sector's 'Minimally Viable' Concept Teach Biopharma? 10/9/2025

   Deciding what is good enough to get started can support the mindset of building something without sacrificing quality, functionality, or safety.

2. Early Immune Profiling With In Vivo, In Vitro, And Ex Vivo Systems 10/7/2025

   Modern biologics increasingly interact with the immune system. While these innovations enable transformative therapies, they can also provoke acute immune activation during first-in-human (FIH) trials.

3. Full-Service Client Support For A Late Clinical-Stage Oncology Biotech 10/2/2025

   This case underscores the expertise employed in a comprehensive strategy and set of services that were used to salvage a Phase III clinical trial for ovarian cancer and ensure its timely completion.

4. Precision Medicine: Targeted Cancer Therapies 10/2/2025

   Cancer research is entering a new precision-driven era, with targeted therapies focusing on the specific genetic or molecular mechanisms that fuel tumor growth.

5. Specialized Site Network For Early-Phase Oncology Success 10/2/2025

   Early-phase oncology trials are complex, demanding precision, rapid execution, and specialized expertise. Yet, too often, the operational burden falls on clinical sites―already overworked and stretched thin. Within large, volume-driven CRO networks, this creates a system that prioritizes scale over quality, offering minimal site support, delaying timelines, and ultimately compromising trial outcomes.

6. Benefits Of Working With Catalyst Oncology Versus A Large Generalist CRO 10/2/2025

   Specialty oncology CROs bridge the gap between traditional CRO operating models and the specialized needs of oncology sponsors by embedding deep oncology expertise across every function.

7. Key Takeaways From ADCs In Oncology Trials Webinar 10/2/2025

   By aligning cutting-edge design with evolving regulatory expectations, sponsors can unlock the full therapeutic potential of ADCs and deliver transformative cancer treatments to patients worldwide.

8. BlueRock Advances Cell Therapy For Parkinson's Disease 9/30/2025

   BlueRock Therapeutics has advanced its allogeneic stem cell-derived therapy bemdaneprocel into the pivotal Phase III trial for Parkinson’s disease, aiming to restore regulated dopamine signaling, improve quality of life, and potentially transform the treatment paradigm.

9. What Do Cancer Patients Really Want From mHealth Technology? 9/30/2025

   What do cancer patients really want from apps and wearables? This piece reveals how patient perspectives can guide mHealth design to reduce burden, build trust, and make digital oncology tools truly meaningful.

10. Rethinking Recruitment: Patient-Centric Strategies For The Future Of Clinical Trials 9/30/2025

    For sponsors and CROs, the message is clear: recruitment must be redesigned for accessibility, inclusivity, and patient trust.